Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Real-Time Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down17.740 -0.500 (-2.741%)
Research Report

17/01/2020 10:48

{I-bank focus}Jefferies lifts CSPC Pharma (01093) to HK$22.5

[ET Net News Agency, 17 January 2020] Jefferies Research lifted its target price for
CSPC Pharmaceutical (01093) to HK$22.5 from HK$19.7 and maintained its "buy" rating.
The research house said CSPC is Jefferies' top pick for 2020 given its relatively high
growth visibility in the next three years, the progressive launch of more than 70 new
products in 2019-22 and valuation discount over other large HK-listed pharmaceutical
Jefferies expects share price pressure following the upcoming centralized procurement on
17 January to provide a good entry point for this name.
Even taking into account the potential ASP cut on Keaili starting in 2020, and ASP cut
on other generic products starting in 2021, Jefferies still expects revenue growth of
22.1%/21.5% in 2020/21 and net profit growth of 18.9%/18.5%. (KL)

Remark: Real time quote last updated: 28/02/2020 10:28
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2020 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.